Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USP704
- Development stage
- Preclinical
- Lead developer
- Uscare Pharm
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
01
Overview
USP704 is an investigational therapeutic candidate currently in the discovery stage for the treatment of degenerative arthritis (osteoarthritis). Developed by Uscare Pharm, a South Korean biotechnology company specializing in biomaterials and drug delivery systems, USP704 is categorized within the company's "Product Innovation" pipeline. The program likely leverages Uscare Pharm's proprietary material technologies, such as biocompatible polymers or hydrogels, to deliver therapeutic agents or provide structural support to degenerated joints. As of 2024, specific details regarding the drug's molecular target and mechanism of action remain undisclosed in public clinical and scientific literature.
Beyond the preview
Go deeper on USP704.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP704.